Min-Tsun Liao1, Lian-Yu Lin2, Yao-Hsu Yang3, Tin-Tse Lin2, Jiunn-Lee Lin2, Pau-Chung Chen4, Chia-Ti Tsai2. 1. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan; 2. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 3. Department for Traditional Chinese Medicine, Chang Gung Memorial Hospital Chia-Yi, Taiwan; ; Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan. 4. Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan.
Abstract
PUPOSE: Atrial fibrillation (AF) is associated with increased risk of thromboembolism, and is also a predisposing factor to dementia. Our investigation was a retrospective observational study to evaluate whether the usage of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) could reduce the incidence of dementia in patients with AF. METHODS: A total of 5221 patients over 20 years of age who had a history of AF as noted in ambulatory and inpatient claims data were enrolled from the National Health Insurance Research Database of Taiwan in 1997 and 1998. Patients with ACEI or ARB were designated as group 1 (4343 patients), and patients without ACEI or ARB were designated as group 2 (878 patients). RESULTS: During a follow-up of 5.90 ± 3.39 years, 135 patients of group 1 (3.1%) and 25 of group 2 (2.8%) developed new-onset dementia. Group 1 and group 2 had similar proportions of new-onset dementia (p = 0.75). The Kaplan-Meier curve demonstrated that patients with ACEI or ARB were not associated with a lower incidence of dementia during the follow-up period (log rank p = 0.91). Cox-regression analysis also showed that usage of ACEI or ARB was not associated with a lower risk of new-onset dementia after adjustment for gender and comorbidities. (Hazard ratio = 0.942, 95% confidence interval 0.589~1.506, and p = 0.80). CONCLUSIONS: ACEI or ARB may be ineffective in reducing the incidence of dementia in patients with AF. KEY WORDS: Angiotensin-converting-enzyme inhibitor; Angiotensin II receptor blocker; Atrial fibrillation; Dementia.
PUPOSE: Atrial fibrillation (AF) is associated with increased risk of thromboembolism, and is also a predisposing factor to dementia. Our investigation was a retrospective observational study to evaluate whether the usage of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) could reduce the incidence of dementia in patients with AF. METHODS: A total of 5221 patients over 20 years of age who had a history of AF as noted in ambulatory and inpatient claims data were enrolled from the National Health Insurance Research Database of Taiwan in 1997 and 1998. Patients with ACEI or ARB were designated as group 1 (4343 patients), and patients without ACEI or ARB were designated as group 2 (878 patients). RESULTS: During a follow-up of 5.90 ± 3.39 years, 135 patients of group 1 (3.1%) and 25 of group 2 (2.8%) developed new-onset dementia. Group 1 and group 2 had similar proportions of new-onset dementia (p = 0.75). The Kaplan-Meier curve demonstrated that patients with ACEI or ARB were not associated with a lower incidence of dementia during the follow-up period (log rank p = 0.91). Cox-regression analysis also showed that usage of ACEI or ARB was not associated with a lower risk of new-onset dementia after adjustment for gender and comorbidities. (Hazard ratio = 0.942, 95% confidence interval 0.589~1.506, and p = 0.80). CONCLUSIONS: ACEI or ARB may be ineffective in reducing the incidence of dementia in patients with AF. KEY WORDS: Angiotensin-converting-enzyme inhibitor; Angiotensin II receptor blocker; Atrial fibrillation; Dementia.
Authors: Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: T Jared Bunch; Brian G Crandall; J Peter Weiss; Heidi T May; Tami L Bair; Jeffrey S Osborn; Jeffrey L Anderson; Joseph B Muhlestein; Benjamin D Horne; Donald L Lappe; John D Day Journal: J Cardiovasc Electrophysiol Date: 2011-03-15
Authors: Anne Cecilie K Larstorp; Inger Ariansen; Knut Gjesdal; Michael H Olsen; Hans Ibsen; Richard B Devereux; Peter M Okin; Björn Dahlöf; Sverre E Kjeldsen; Kristian Wachtell Journal: Hypertension Date: 2012-07-02 Impact factor: 10.190
Authors: Stefan Knecht; Christian Oelschläger; Thomas Duning; Hubertus Lohmann; Johannes Albers; Christoph Stehling; Walter Heindel; Günter Breithardt; Klaus Berger; E Bernd Ringelstein; Paulus Kirchhof; Heike Wersching Journal: Eur Heart J Date: 2008-07-29 Impact factor: 29.983